-transparent.png){kind=logo}
Pre-clinical studies have suggested that one mechanism of antimigraine action of the 'triptan' 5-HT1B/1D receptor agonists may be through inhibition of central nociceptive transmission in the trigeminal dorsal horn. In anaesthetized rats, the 5-HT1B/1D receptor agonist, zolmitriptan (up to 3 mg kg(-1), i.v.), inhibited the action potential discharge of single trigeminal neurones to noxious electrical stimulation of the middle meningeal artery. In contrast, the selective 5-HT1B receptor agonist, CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one), and the 5-HT1A receptor selective agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) had no effect in this assay at up to 3 mg kg(-1), i.v.. Brain penetrant, triptan 5-HT1B/1D receptor agonists may therefore mediate their central trigeminal anti-nociceptive action in the rat via 5-HT1D, but not 5-HT1B or 5-HT1A, receptors.
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
July 1995,
European journal of pharmacology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
January 1997,
Neuropharmacology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
June 1989,
Naunyn-Schmiedeberg's archives of pharmacology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
September 1995,
No to shinkei = Brain and nerve,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
April 1990,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
October 1995,
British journal of pharmacology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
January 2010,
Neuroscience,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
April 2007,
Neuroscience letters,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
December 2008,
Brain : a journal of neurology,
M J Cumberbatch, and
R G Hill, and
R J Hargreaves
June 1990,
European journal of pharmacology,
